Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03459846
Title A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU)
Acronym BAYOU
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | ESP | CAN

No variant requirements are available.